Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition.

LMP7 ONX 0914 Prostate cancer TRAMP castration-resistant prostate cancer (CRPC) immunoproteasome myeloid-derived suppressor cells (MDSC)

Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
2023
Historique:
entrez: 19 12 2022
pubmed: 20 12 2022
medline: 21 12 2022
Statut: epublish

Résumé

New treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are key mediators to promote growth of PC. Here, we evaluate the potential of immunoproteasome inhibition for anti-inflammatory and direct anti-tumorigenic therapy of PC. The anti-tumor effect of immunoproteasome inhibitor ONX 0914 was tested in mouse and human PC cells and the

Identifiants

pubmed: 36531689
doi: 10.1080/2162402X.2022.2156091
pii: 2156091
pmc: PMC9757486
doi:

Substances chimiques

Proteasome Endopeptidase Complex EC 3.4.25.1
Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2156091

Informations de copyright

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

Déclaration de conflit d'intérêts

The authors report there are no competing interests to declare.

Références

Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Int J Oncol. 2019 Apr;54(4):1357-1366
pubmed: 30720063
Prostate. 2005 Feb 1;62(2):148-64
pubmed: 15389804
Science. 1994 Aug 26;265(5176):1234-7
pubmed: 8066463
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Pol J Pathol. 2020;71(1):46-54
pubmed: 32429654
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Int J Clin Exp Med. 2014 Oct 15;7(10):3181-92
pubmed: 25419348
EMBO Rep. 2018 Dec;19(12):
pubmed: 30279279
J Immunol. 2010 Mar 1;184(5):2281-8
pubmed: 20118280
J Immunol. 2010 Nov 1;185(9):5549-60
pubmed: 20881186
Mol Cell Biol. 2014 Jun;34(11):2017-28
pubmed: 24662052
Clin Cancer Res. 2018 Sep 1;24(17):4309-4318
pubmed: 29776955
J Clin Oncol. 2004 Jun 1;22(11):2108-21
pubmed: 15169797
Cell. 2017 May 18;169(5):792-806
pubmed: 28525752
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
EMBO Mol Med. 2014 Feb;6(2):226-38
pubmed: 24399752
Nat Rev Drug Discov. 2013 Sep;12(9):703-19
pubmed: 23989796
Oncogene. 2017 Feb 2;36(5):687-699
pubmed: 27375020
Clin Cancer Res. 2008 Jun 1;14(11):3254-61
pubmed: 18519750
J Immunol Methods. 1999 Feb 1;223(1):77-92
pubmed: 10037236
Int J Cancer. 2009 Sep 15;125(6):1372-9
pubmed: 19533748
J Immunother Cancer. 2014 Sep 16;2:31
pubmed: 26196012
Ann Oncol. 2015 Apr;26(4):750-755
pubmed: 25538172
Kidney Int. 2019 Mar;95(3):611-623
pubmed: 30685098
Nat Rev Urol. 2018 Jan;15(1):11-24
pubmed: 29089606
Int J Colorectal Dis. 2009 Oct;24(10):1133-9
pubmed: 19274467
Prostate. 2014 Jun;74(8):869-79
pubmed: 24691769
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
pubmed: 7724580
Am J Pathol. 2008 Jan;172(1):236-46
pubmed: 18156212
Prostate. 2003 May 15;55(3):219-37
pubmed: 12692788
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
J Immunol. 2010 Jul 1;185(1):634-41
pubmed: 20525886
Nat Rev Immunol. 2010 Jan;10(1):73-8
pubmed: 20010787
IUBMB Life. 2018 May;70(5):445-457
pubmed: 29537730
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S74-9
pubmed: 26458097
Cancer Cell. 2011 Apr 12;19(4):429-31
pubmed: 21481782
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
J Leukoc Biol. 2020 Jan;107(1):43-56
pubmed: 31721301
Br J Cancer. 2012 Jun 26;107(1):53-62
pubmed: 22677907
Oncotarget. 2017 Feb 7;8(31):50873-50888
pubmed: 28881611
Nat Rev Cancer. 2020 Aug;20(8):455-469
pubmed: 32546840
Cancer Res. 1996 Sep 15;56(18):4096-102
pubmed: 8797572
BJU Int. 2011 Jun;107(12):1918-22
pubmed: 21044246
Oncotarget. 2017 Jan 10;8(31):50447-50459
pubmed: 28881574
J Immunol. 2019 Oct 1;203(7):1776-1785
pubmed: 31484727
Toxicol Pathol. 2012;40(1):5-17
pubmed: 22021166
Prostate. 2017 Jun;77(8):888-899
pubmed: 28240383
Clin Cancer Res. 2015 Aug 15;21(16):3771-82
pubmed: 25967142
Cancer Res. 1997 Nov 1;57(21):4687-91
pubmed: 9354422
Nat Med. 2009 Jul;15(7):781-7
pubmed: 19525961
Cancer Res. 2004 May 1;64(9):3334-43
pubmed: 15126378

Auteurs

Julia Koerner (J)

Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.

Dennis Horvath (D)

Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany.

Franziska Oliveri (F)

Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.

Jun Li (J)

Department of Urologic Oncology Surgery, Chongqing University Cancer Hospital, Chongqing, China.

Michael Basler (M)

Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany.
Biotechnology Institute Thurgau (BITg) at the University of Konstanz, Kreuzlingen, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH